Therapeutic strategies targeting adiponectin hold promise for improving metabolic profiles and cardiovascular health, particularly in conditions characterized by decreased adiponectin levels, such as atherosclerosis, insulin resistance, and CVD [65]. The gene discussed is ADIPOQ; the disease is Insulin resistance.